Sanofi-Aventis to expand diabetes portfolio in $375 million deal for Metabolex products

28 June 2010

Announcing a second major licensing deal in the same week, French drug major Sanofi-Aventis last Friday entered into a global licensing accord with USA-based and Metabolex for oral agent MBX-2982, a GPR1 19 receptor agonist for the treatment of type 2 diabetes, with the aim of further expanding its already significant footprint in this therapeutic area.

Just two days earlier, Sanofi-Aventis confirmed its research interest into the microRNA sector, signing a strategic alliance with US firm Regulus Therapeutics to discover, develop and commercialize microRNA therapeutics which could earn the latter as much as $750 million (The Pharma Letter June 23). This month, the French group also entered licensing deals with US companies Vivalis and Ascenta and with Germany's Charite University (TPLs passim).

Product in Phase IIa development

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK